These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 33529588)

  • 21. Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.
    Evans D; Kenyon K; Ousler G; Watson M; Vollmer P; McLaurin EB; Torkildsen G; Winters J; Dodd J; Jordan R; Wills ST; Spana C
    J Ocul Pharmacol Ther; 2023 Nov; 39(9):600-610. PubMed ID: 37677000
    [No Abstract]   [Full Text] [Related]  

  • 22. Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial.
    Peng W; Jiang X; Zhu L; Li X; Zhou Q; Jie Y; You Z; Wu M; Jin X; Li X; Zhou S
    Drug Des Devel Ther; 2022; 16():3183-3194. PubMed ID: 36164414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
    Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
    Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies.
    Leonardi A; Messmer EM; Labetoulle M; Amrane M; Garrigue JS; Ismail D; Sainz-de-la-Maza M; Figueiredo FC; Baudouin C
    Br J Ophthalmol; 2019 Jan; 103(1):125-131. PubMed ID: 29545413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Water-Free Cyclosporine Ophthalmic Solution vs Vehicle for Dry Eye Disease: A Randomized Clinical Trial.
    Peng R; Jie Y; Long Q; Gong L; Zhu L; Zhong X; Zhao S; Yan X; Gu H; Wu H; Li G; Zhang K; Krösser S; Xu R; Hong J
    JAMA Ophthalmol; 2024 Apr; 142(4):337-343. PubMed ID: 38451509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
    Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
    Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: The Randomized Phase 3 MOJAVE Study.
    Sheppard JD; Kurata F; Epitropoulos AT; Krösser S; Vittitow JL;
    Am J Ophthalmol; 2023 Aug; 252():265-274. PubMed ID: 36948372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, vehicle-controlled, Phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1).
    Wirta DL; Senchyna M; Lewis AE; Evans DG; McLaurin EB; Ousler GW; Hollander DA
    Ocul Surf; 2022 Oct; 26():166-173. PubMed ID: 35970431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.
    Stevenson D; Tauber J; Reis BL
    Ophthalmology; 2000 May; 107(5):967-74. PubMed ID: 10811092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topical Fluorometholone Protects the Ocular Surface of Dry Eye Patients from Desiccating Stress: A Randomized Controlled Clinical Trial.
    Pinto-Fraga J; López-Miguel A; González-García MJ; Fernández I; López-de-la-Rosa A; Enríquez-de-Salamanca A; Stern ME; Calonge M
    Ophthalmology; 2016 Jan; 123(1):141-53. PubMed ID: 26520171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial.
    Wirta D; Vollmer P; Paauw J; Chiu KH; Henry E; Striffler K; Nau J;
    Ophthalmology; 2022 Apr; 129(4):379-387. PubMed ID: 34767866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China.
    Dong Y; Wang S; Cong L; Zhang T; Cheng J; Yang N; Qu X; Li D; Zhou X; Wang H; Lee M; Wang M; Chen S; Ousler GW; Chen X; Xie L
    Int Ophthalmol; 2022 Aug; 42(8):2459-2472. PubMed ID: 35192105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye.
    Kinoshita S; Awamura S; Nakamichi N; Suzuki H; Oshiden K; Yokoi N;
    Am J Ophthalmol; 2014 Mar; 157(3):576-83.e1. PubMed ID: 24246575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease.
    Goldstein MH; Martel JR; Sall K; Goldberg DF; Abrams M; Rubin J; Sheppard J; Tauber J; Korenfeld M; Agahigian J; Durham TA; Furfine E
    Eye Contact Lens; 2017 Sep; 43(5):287-296. PubMed ID: 27466718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.
    Semba CP; Torkildsen GL; Lonsdale JD; McLaurin EB; Geffin JA; Mundorf TK; Kennedy KS; Ousler GW
    Am J Ophthalmol; 2012 Jun; 153(6):1050-60.e1. PubMed ID: 22330307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study.
    Chen D; Zhang S; Bian A; Hong J; Deng Y; Zhang M; Chen W; Shao Y; Zhao J
    Medicine (Baltimore); 2019 Aug; 98(31):e16710. PubMed ID: 31374063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized, Multicenter, Double-Blind Study of the Safety and Efficacy of 1%D-3-Hydroxybutyrate eye drops for Dry Eye Disease.
    Kawakita T; Uchino M; Fukagawa K; Yoshino K; Shimazaki S; Toda I; Tanaka M; Arai H; Sakatani K; Hata S; Okano T; Tsubota K
    Sci Rep; 2016 Feb; 6():20855. PubMed ID: 26865350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood derived treatment from two allogeneic sources for severe dry eye associated to keratopathy: a multicentre randomised cross over clinical trial.
    Campos E; Versura P; Buzzi M; Fontana L; Giannaccare G; Pellegrini M; Lanconelli N; Brancaleoni A; Moscardelli F; Sebastiani S; Vaselli C; Randi V
    Br J Ophthalmol; 2020 Aug; 104(8):1142-1147. PubMed ID: 31744796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Single-dose OC-02 (Simpinicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The PEARL Phase II Randomized Trial.
    Torkildsen GL; Pattar GR; Jerkins G; Striffler K; Nau J
    Clin Ther; 2022 Sep; 44(9):1178-1186. PubMed ID: 35965109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.